This has led to the development of anti-IL-6 therapies that, despite the decreased phosphorylation of STAT3 and p44/p42 MAPK as well as suppressing IL-6 downstream signaling [326], failed to improve the survival of patients with metastatic PCa in clinical trials [327,328]. This evidence concerns the gene IL6 and posterior cortical atrophy.